This small-cap Pharma Stock, engaged in manufacturing and R&D of pharmaceuticals, offering tablets, capsules, injectables, syrups, eye drops, and various formulations, jumped 7 percent after the company reported a net profit growth of 43,516 percent in the financial year 2025.
With a market capitalization of Rs. 9,172.13 crores, the share of Akums Drugs and Pharmaceuticals Limited has reached an intraday high of Rs. 620 per equity share, rising nearly 6.52 percent from its previous day’s close price of Rs. 582.05. Since then, the stock has retreated and is currently trading at Rs. 582.75 per equity share.
Q4 FY25 Result Walkthrough:
Coming into the quarterly results of Akums Drugs and Pharmaceuticals Limited, the company’s consolidated revenue from operations increased by 11.79 percent YOY, from Rs. 944.21 crore in Q4 FY24 to Rs. 1,055.55 crore in Q4 FY25, and grew by 4.47 percent QoQ from Rs. 1,010.41 crore in Q3 FY25.
Akums Drugs and Pharmaceuticals Limited generated 79.44 percent of its revenue from CDMO, 5.87 percent from API, 9.14 percent from domestic branded formulations, 3.50 percent from international branded formulations, and 2.05 percent from trade generics in Q4 FY25.
In Q4 FY25, Akums Drugs and Pharmaceuticals Limited’s consolidated net profit has turned from negative to positive, from a net loss of Rs. 39.47 crore in Q4 FY24 to a net profit of Rs. 149.61 crore in Q4 FY25. Compared to Q3 FY25, the net profit has increased by 125.62 percent, from Rs. 66.31 crore. The basic earnings per share increased by 126.29 percent and stood at Rs. 9.64 as against Rs. 4.26 recorded in the previous quarter in the financial year 2025.
FY25 Result: Akums Drugs and Pharmaceuticals Limited’s revenue has decreased from Rs. 4178.18 crore in FY24 to Rs. 4118.16 crore in FY25, which is a drop of 1.44 percent. The net profit has grown by 43,516.46 percent, from Rs. 0.79 crore in FY24 to Rs. 343.78 crore in FY25.
Akums Drugs and Pharmaceuticals Limited was founded in 2004 by Sanjeev Jain and Sandeep Jain. The company is a leading Indian pharmaceutical Contract Development and Manufacturing Organization (CDMO), serving both domestic and multinational pharmaceutical companies.
The company operates 15 manufacturing facilities for different types of formulations and three facilities for active pharmaceutical ingredients (APIs). It also has four R&D centers in India. Its wide product range includes tablets, capsules, soft gels, dry syrups, liquid orals, injectables, vials, ampoules, eye drops, and FFS formulations.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
